Validation of CATCH-U-DNA using model and clinical samples

To develop robust assay conditions and standardize the proposed method for mutation detection, we will evaluate the lower level of sensitivity by spiking varying amounts of mixture DNA samples with different mixing ratios between the mutant and wild-type DNA templates into peripheral blood plasma from healthy donors. Partner 4 will be responsible for collecting blood samples from patients with lung or colorectal cancer and identifying particular mutations using next generation sequencing (NGS) or qPCR. Serum from the analyzed clinical samples carrying common mutations occurring in colorectal and lung cancers, such as, KRAS, EGFR, and BRAF will be kept and provided to FORTH partner for the validation of the detection method using the developed acoustic wave platform. The results will be compared to the findings of P4 using the NGS and real-time PCR.